Literature DB >> 2832187

Differences in results from in vivo and in vitro studies on the use-dependency of N-methylaspartate antagonism by MK-801 and other phencyclidine receptor ligands.

S N Davies1, D Martin, J D Millar, J A Aram, J Church, D Lodge.   

Abstract

We have used microelectrophoretic and intravenous administration of drugs to rat spinal cord neurones in vivo and bath application to rat cortical wedges in vitro to evaluate MK-801 and other phencyclidine (PCP) receptor ligands as N-methylaspartate (NMA) antagonists, paying particular regard to the possible use-dependent nature of their action. MK-801, 0.1-0.5 mg/kg, was a selective and long-lasting NMA antagonist. We were unable to demonstrate significant use-dependent onset of antagonism of NMA by any of the drugs in vivo. Recovery, however, for MK-801 was use-dependent. In vitro there was a gradation with MK-801 being very use-dependent, followed by (PCP), cyclazocine and ketamine, the last showing little or no use-dependence. Results of experiments modulating the in vitro environment suggest that a significant difference between the in vitro and in vivo systems was temperature. Raising the temperature of the wedge chamber from 23 to 33 degrees C reduced the use-dependence of MK-801, and lowering the temperature to 13 degrees C increased the use-dependence of PCP. The mechanism of action of PCP receptor ligands is discussed in the light of these results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832187     DOI: 10.1016/0014-2999(88)90225-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  Ca2+ entry pathways in mouse spinal motor neurons in culture following in vitro exposure to methylmercury.

Authors:  Gunasekaran Ramanathan; William D Atchison
Journal:  Neurotoxicology       Date:  2011-08-02       Impact factor: 4.294

Review 2.  Excitatory amino acid receptors in normal and abnormal vestibular function.

Authors:  P F Smith; C de Waele; P P Vidal; C L Darlington
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

3.  A comparison between the in vivo and in vitro activity of five potent and competitive NMDA antagonists.

Authors:  D Lodge; S N Davies; M G Jones; J Millar; D T Manallack; P L Ornstein; A J Verberne; N Young; P M Beart
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

Review 4.  A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex.

Authors:  P L Wood; T S Rao; S Iyengar; T Lanthorn; J Monahan; A Cordi; E Sun; M Vazquez; N Gray; P Contreras
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 5.  The postnatal development of spinal sensory processing.

Authors:  M Fitzgerald; E Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 6.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

7.  Effects of pH on the actions of dizocilpine at the N-methyl-D-aspartate receptor complex.

Authors:  S Rajdev; I J Reynolds
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

8.  Behavioral studies on FR115427, a novel selective N-methyl-D-aspartate antagonist.

Authors:  H Nakanishi; K Katsuta; Y Ueda; H Takasugi; A Kuno; M Ohkubo; K Ogita; Y Yoneda; K Shirakawa; K Yoshida
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.

Authors:  T Frankiewicz; B Potier; Z I Bashir; G L Collingridge; C G Parsons
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.